DE60003151D1 - Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen - Google Patents

Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen

Info

Publication number
DE60003151D1
DE60003151D1 DE60003151T DE60003151T DE60003151D1 DE 60003151 D1 DE60003151 D1 DE 60003151D1 DE 60003151 T DE60003151 T DE 60003151T DE 60003151 T DE60003151 T DE 60003151T DE 60003151 D1 DE60003151 D1 DE 60003151D1
Authority
DE
Germany
Prior art keywords
cytokines
nucleic acids
simultaneous administration
genetic immunization
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003151T
Other languages
English (en)
Other versions
DE60003151T2 (de
Inventor
Quin Liu
Ruijiang Song
Thomas August
W Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60003151D1 publication Critical patent/DE60003151D1/de
Publication of DE60003151T2 publication Critical patent/DE60003151T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60003151T 1999-01-13 2000-01-13 Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen Expired - Fee Related DE60003151T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11584999P 1999-01-13 1999-01-13
US115849P 1999-01-13
US11624299P 1999-01-15 1999-01-15
US116242P 1999-01-15
PCT/US2000/000730 WO2000041679A1 (en) 1999-01-13 2000-01-13 Genetic immunization with co-delivery of nucleic acid and cytokines

Publications (2)

Publication Number Publication Date
DE60003151D1 true DE60003151D1 (de) 2003-07-10
DE60003151T2 DE60003151T2 (de) 2004-04-08

Family

ID=26813643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003151T Expired - Fee Related DE60003151T2 (de) 1999-01-13 2000-01-13 Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen

Country Status (4)

Country Link
EP (1) EP1143934B1 (de)
AT (1) ATE241965T1 (de)
DE (1) DE60003151T2 (de)
WO (1) WO2000041679A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211710A1 (en) 2000-10-13 2002-04-22 Chiron Corporation Cytomegalovirus intron a fragments
CA2433794A1 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
EP1697511A4 (de) * 2003-12-11 2007-11-21 Vaxdesign Corp Immuntherapiezusammensetzungen, verfahren zur herstellung und verfahren zur verwendung davon
CA2566199C (en) * 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
PT1765294E (pt) 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
EP2068917A2 (de) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Zusammensetzungen und verfahren für eine chitosan-verstärkte immunreaktion
EP2175841A1 (de) * 2007-07-16 2010-04-21 Aarhus Universitet Osteopontin-nanoteilchen-system zur arzneiabgabe
EP2417968A1 (de) * 2010-07-29 2012-02-15 Consorzio per il Centro di Biomedicina Molecolare Scrl Partikel mit Cytokinen, Antikörpern und Polymeren und deren Verwendung als Arzneimittel zur Behandlung von Krebs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2704145B1 (fr) * 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
EP0705096A1 (de) * 1993-06-22 1996-04-10 Novartis AG Albumin mikrokugeln mit modifizierter oberfläche und pharmazeutische zusammensetzungen, die sie enthalten
AU7208494A (en) * 1993-07-28 1995-02-28 Johns Hopkins University School Of Medicine, The Controlled release of pharmaceutically active substances from coacervate microcapsules
EP0769063A1 (de) * 1994-06-27 1997-04-23 The Johns Hopkins University Gezielte freigabe genetischen materials
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
WO2000041679A1 (en) 2000-07-20
DE60003151T2 (de) 2004-04-08
EP1143934B1 (de) 2003-06-04
EP1143934A1 (de) 2001-10-17
ATE241965T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
DE60003151D1 (de) Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
CA2123580A1 (en) Antigen of hybrid m protein and carrier for group a streptococcal vaccine
DK0642355T3 (da) Kombinerede vacciner, der omfatter hepatitis B-overfladeantigen og andre antigener
ES2092306T3 (es) Adyuvante para vacunas.
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
ES2170075T3 (es) Vacuna de proteina m recombinante multivalente.
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
NO904806D0 (no) Rekombinante flagellin-vaksiner.
AU2002245756A1 (en) Identification and modification of immunodominant epitopes in polypeptides
CA2393251A1 (en) Eliciting hcv-specific antibodies
IT1180160B (it) Antigene di peptide protettivo
NO20015074D0 (no) Nye sammensetninger
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DE69332501T2 (de) Herpesvirus impfstoffe
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
CA2128247A1 (en) Vaccines based on streptokinase
GB2227936A (en) Vaccine against brucella abortus
WO1999053960A3 (en) Enhancing immune responses to genetic immunization by using a chemokine
ES2166763T3 (es) Inmunizacion parenteral contra rotavirus.
HK1025220A1 (en) Novel saponin compositions and uses thereof
EP1401470A4 (de) Neue antikörper, die an antigene polypeptide binden, die antigene kodierende nukleinsäuren und verfahren zu ihrer anwendung
Heath Cytokines and the rational choice of immunological adjuvants

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee